Equity Details
Price & Market Data
Price: $11.56
Daily Change: +$1.61 / 13.93%
Daily Range: $9.91 - $12.05
Market Cap: $624,217,536
Daily Volume: 407,681
Performance Metrics
1 Week: 12.16%
1 Month: 16.82%
3 Months: -15.16%
6 Months: -32.38%
1 Year: -32.38%
YTD: -23.13%
About Eikon Therapeutics, Inc. (EIKN)
Financial summary for Eikon Therapeutics, Inc. (EIKN). Price: 11.56, daily change: +$1.61 / 13.93%. Market cap: 624,217,536. Performance for all periods at a glance.
Details
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs using a platform that permits precise characterization of protein interactions in living cells. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.